An observational study in Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis and Pulmonary Eosinophilia, sponsored by Matthias Griese. Recruiting at 3 sites in 3 countries. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Matthias Griese · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Pulmonary Fibrosis with a site in Germany — 4 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Fibrosis · Germany.
Among the 25 studies in Pulmonary Fibrosis with a site in Germany, this one is one of 2 that started in 2013, is one of 4 observational ones, and was the 8th registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →4 of the 25 studies in Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:
Contineum Therapeutics · Sites in Germany, Argentina, Australia and 16 more countries
Ages 40+
University of Ulm · Sites in Germany
Ages 18–90 · Healthy volunteers
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 24 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.
Median enrollment 320 across the 21 interventional studies, 345 across the 4 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 25 have an industry lead sponsor. The 10 most frequent:
Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Matthias Griese has 1 study filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Fibrosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Pulmonary Fibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes
Objective 1: Generation of a common European database and biobank. The existing national programmes to collect data on chILD in three countries (France, Germany, UK) will enable the consortium to swiftly adapt current frameworks to a functionally appropriate pan-European web-based database and biobank. Importantly, compatibility with ongoing United States chILD data base developments will be factored in.
Objective 2: Continuous assessment and implementation of guidelines and treatment protocols. Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific diagnostic pathways, including detailed protocols for gathering clinical information, blood testing, imaging and pathology ("Best Practice Checklist"); (b) international panels of clinicians, geneticists, radiologists and pathologists who will review every diagnosis to quality control the data; and (c) detailed protocols for follow up to generate natural history data.
Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide recruitment and interdisciplinary critical peer review of all diagnoses submitted from across Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis is possible, we will review the case periodically as new information becomes available. During the first year of the study, clinicians´ decisions according to local practice and outcomes will be independently monitored and assessed.
Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize and clarify the relative weight of a large spectrum of single and composite clinical outcomes (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation exposure), lung function testing, histopathological categorization of lung biopsies, serum markers and genetic tests. Variability, reproducibility and the effects of training on reading images will be investigated.
Objective 5: Assess treatment variations used, deliver data from defined protocols and linked outcomes. This project will analyse in detail treatment and outcomes within and between subjects using data collected. Analysis of the collected data will enable us to support the definition of trial protocols planned in the future.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →
400 prevalent patients with childhood interstitial lung disease (chILD) in Europe 100 incident chILD cases per year
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Included subjects with specific diagnosis
Number of recruited subjects
Time frame: 10 years
Survial
Survival of the participants
Time frame: 10 years
Plan to share: No
Started Dec 2013 (actual). Primary completion is estimated for Dec 2028, 180 months after the start.
Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 180 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Matthias Griese